Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease
Obesity and steatosis have been associated with liver disease progression in patients with compensated advanced chronic liver disease (cACLD) (liver stiffness measurement [LSM] ≥ 10 kPa). The controlled attenuation parameter (CAP) estimates steatosis during LSM by transient elastography. We aimed to...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-08-01
|
Series: | Hepatology Communications |
Online Access: | https://doi.org/10.1002/hep4.1201 |
id |
doaj-d54e57768a624cfbb57e7c48b2ac80e6 |
---|---|
record_format |
Article |
spelling |
doaj-d54e57768a624cfbb57e7c48b2ac80e62020-11-25T02:01:52ZengWileyHepatology Communications2471-254X2018-08-012893394410.1002/hep4.1201Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver DiseaseCristina Margini0Giuseppe Murgia1Guido Stirnimann2Andrea De Gottardi3Nasser Semmo4Stefania Casu5Jaime Bosch6Jean‐François Dufour7Annalisa Berzigotti8Swiss Liver Center, Hepatology University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern Bern SwitzerlandSwiss Liver Center, Hepatology University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern Bern SwitzerlandSwiss Liver Center, Hepatology University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern Bern SwitzerlandSwiss Liver Center, Hepatology University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern Bern SwitzerlandSwiss Liver Center, Hepatology University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern Bern SwitzerlandSwiss Liver Center, Hepatology University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern Bern SwitzerlandSwiss Liver Center, Hepatology University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern Bern SwitzerlandSwiss Liver Center, Hepatology University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern Bern SwitzerlandSwiss Liver Center, Hepatology University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern Bern SwitzerlandObesity and steatosis have been associated with liver disease progression in patients with compensated advanced chronic liver disease (cACLD) (liver stiffness measurement [LSM] ≥ 10 kPa). The controlled attenuation parameter (CAP) estimates steatosis during LSM by transient elastography. We aimed to evaluate whether CAP is associated with the development of clinically relevant events in cACLD. Consecutive patients with cACLD and CAP measurements observed between September 2013 and September 2015 were retrospectively studied. Classical decompensation and severe bacterial infections on follow‐up were recorded. A predefined CAP cut‐off for steatosis was used (220 dB/m; 90% sensitivity). The association among LSM, CAP, and events was assessed by univariate and multivariate Cox regression. Among the 193 patients (viral etiology = 58%; median Child score = 5; LSM = 15.1 kPa; CAP = 255 ± 62 dB/m) who were followed up in median for 18 months, 18 developed clinically relevant events (11 liver decompensation, 7 severe bacterial infections). Patients developing events had higher LSM (median: 30.8 versus 14.3 kPa, P < 0.001) and showed trends for higher CAP (275 ± 46 versus 252 ± 63 dB/m, P = 0.07), lower platelet count (134 ± 74 versus 167 ± 74 G/L, P = 0.07), and worse liver function versus patients remaining compensated. Body mass index was similar in the two groups. All events were more frequent in patients with CAP being greater than or equal to 220 dB/m (12.9% versus 1.6% in CAP < 220; P = 0.013), and 10 of 11 episodes of liver decompensation occurred in patients with CAP being greater than or equal to 220 dB/m. Following multivariate analysis, LSM and CAP greater than or equal to 220 dB/m remained independently associated with clinical events in the whole population and in patients with clinically significant portal hypertension. Conclusion: The CAP being greater than or equal to 220 dB/m is associated with increased risk of clinical decompensation and bacterial infections independent of LSM in patients with cACLD and allows refining the noninvasive risk stratification in this population. (Hepatology Communications 2018; 00:000‐000)https://doi.org/10.1002/hep4.1201 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cristina Margini Giuseppe Murgia Guido Stirnimann Andrea De Gottardi Nasser Semmo Stefania Casu Jaime Bosch Jean‐François Dufour Annalisa Berzigotti |
spellingShingle |
Cristina Margini Giuseppe Murgia Guido Stirnimann Andrea De Gottardi Nasser Semmo Stefania Casu Jaime Bosch Jean‐François Dufour Annalisa Berzigotti Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease Hepatology Communications |
author_facet |
Cristina Margini Giuseppe Murgia Guido Stirnimann Andrea De Gottardi Nasser Semmo Stefania Casu Jaime Bosch Jean‐François Dufour Annalisa Berzigotti |
author_sort |
Cristina Margini |
title |
Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease |
title_short |
Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease |
title_full |
Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease |
title_fullStr |
Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease |
title_full_unstemmed |
Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease |
title_sort |
prognostic significance of controlled attenuation parameter in patients with compensated advanced chronic liver disease |
publisher |
Wiley |
series |
Hepatology Communications |
issn |
2471-254X |
publishDate |
2018-08-01 |
description |
Obesity and steatosis have been associated with liver disease progression in patients with compensated advanced chronic liver disease (cACLD) (liver stiffness measurement [LSM] ≥ 10 kPa). The controlled attenuation parameter (CAP) estimates steatosis during LSM by transient elastography. We aimed to evaluate whether CAP is associated with the development of clinically relevant events in cACLD. Consecutive patients with cACLD and CAP measurements observed between September 2013 and September 2015 were retrospectively studied. Classical decompensation and severe bacterial infections on follow‐up were recorded. A predefined CAP cut‐off for steatosis was used (220 dB/m; 90% sensitivity). The association among LSM, CAP, and events was assessed by univariate and multivariate Cox regression. Among the 193 patients (viral etiology = 58%; median Child score = 5; LSM = 15.1 kPa; CAP = 255 ± 62 dB/m) who were followed up in median for 18 months, 18 developed clinically relevant events (11 liver decompensation, 7 severe bacterial infections). Patients developing events had higher LSM (median: 30.8 versus 14.3 kPa, P < 0.001) and showed trends for higher CAP (275 ± 46 versus 252 ± 63 dB/m, P = 0.07), lower platelet count (134 ± 74 versus 167 ± 74 G/L, P = 0.07), and worse liver function versus patients remaining compensated. Body mass index was similar in the two groups. All events were more frequent in patients with CAP being greater than or equal to 220 dB/m (12.9% versus 1.6% in CAP < 220; P = 0.013), and 10 of 11 episodes of liver decompensation occurred in patients with CAP being greater than or equal to 220 dB/m. Following multivariate analysis, LSM and CAP greater than or equal to 220 dB/m remained independently associated with clinical events in the whole population and in patients with clinically significant portal hypertension. Conclusion: The CAP being greater than or equal to 220 dB/m is associated with increased risk of clinical decompensation and bacterial infections independent of LSM in patients with cACLD and allows refining the noninvasive risk stratification in this population. (Hepatology Communications 2018; 00:000‐000) |
url |
https://doi.org/10.1002/hep4.1201 |
work_keys_str_mv |
AT cristinamargini prognosticsignificanceofcontrolledattenuationparameterinpatientswithcompensatedadvancedchronicliverdisease AT giuseppemurgia prognosticsignificanceofcontrolledattenuationparameterinpatientswithcompensatedadvancedchronicliverdisease AT guidostirnimann prognosticsignificanceofcontrolledattenuationparameterinpatientswithcompensatedadvancedchronicliverdisease AT andreadegottardi prognosticsignificanceofcontrolledattenuationparameterinpatientswithcompensatedadvancedchronicliverdisease AT nassersemmo prognosticsignificanceofcontrolledattenuationparameterinpatientswithcompensatedadvancedchronicliverdisease AT stefaniacasu prognosticsignificanceofcontrolledattenuationparameterinpatientswithcompensatedadvancedchronicliverdisease AT jaimebosch prognosticsignificanceofcontrolledattenuationparameterinpatientswithcompensatedadvancedchronicliverdisease AT jeanfrancoisdufour prognosticsignificanceofcontrolledattenuationparameterinpatientswithcompensatedadvancedchronicliverdisease AT annalisaberzigotti prognosticsignificanceofcontrolledattenuationparameterinpatientswithcompensatedadvancedchronicliverdisease |
_version_ |
1724955346715279360 |